Viking Therapeutics

Metabolic disease therapeutics

VKTX · Nasdaq · United States

Share price · VKTX

$26.17-7.20 (-21.58%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.9M (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VKTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 24 Sep 2026-11.8%
  2. 22 Sep 2026+35.7%
  3. 23 Jul 2026-5.1%
  4. 7 Jul 2026+8.8%

    Nothing announced by VKTX that day or the session before.

  5. 24 Jun 2026+8.8%
  6. 23 Jun 2026+7.5%
  7. 30 Mar 2026-8.0%

    Nothing announced by VKTX that day or the session before.

  8. 23 Feb 2026+11.1%
  9. 12 Feb 2026+6.8%
  10. 5 Feb 2026-11.1%

Share of unusual movement by asset

For each asset, the share of VKTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
VK2735
events and moves
1932%
VK2809
events and moves
2shown from 8 days
VK0214
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—1%
Other company news (earnings, financing, releases naming no asset)—20%
Sessions with no dated event—47%

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
GLP-1/GIP receptor (dual)Peptide
ObesityType 2 Diabetes
Phase 2
Thyroid hormone receptor-betaSmall molecule
MASH / NASH
Phase 1
Thyroid hormone receptor beta (agonist)Small molecule
X-linked Adrenoleukodystrophy

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (2)
VK2735Phase 3Weight Loss
Est. primary completion 2027-07-01 · NCT07104383 · CT.gov ↗
What to watch
VK2735Phase 3Weight Loss
Est. primary completion 2027-07-01 · NCT07104500 · CT.gov ↗
What to watch
2028 (2)
July 2028 (1)
VK2735Phase 3Weight Loss
Est. primary completion 2028-07 · NCT07868835 · CT.gov ↗
What to watch
October 2028 (1)
VK2735Phase 3Weight Loss
Est. primary completion 2028-10 · NCT07868939 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 September 2026Topline resultVK2735Viking reports positive topline results from its VK2735 maintenance study
Global · Viking Therapeutics, Inc. · Source ↗
19 August 2025Topline resultVK2735Phase 2 VENTURE-Oral Dosing of oral VK2735 met its primary endpoint
Viking Therapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$167M$678M+ $282M short-term inv.$183M-$138M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$116M$126M+ $376M short-term inv.$128M-$125M operating cash flowreport ↗
2026-Q1$0$150M$118M+ $485M short-term inv.$158M-$114M operating cash flowreport ↗
2025-Q3$0$90M$100M+ $614M short-term inv.$91M-$94M operating cash flowreport ↗
2025-Q2$0$60M$34M+ $774M short-term inv.$66M-$47M operating cash flowreport ↗
2025-Q1$0$41M$38M+ $814M short-term inv.$46M-$52M operating cash flowreport ↗
2024-Q3$0$23M$50M+ $880M short-term inv.$25M-$22M operating cash flowreport ↗
2024-Q2$0$24M$44M+ $898M short-term inv.$22M-$29M operating cash flowreport ↗
2024-Q1$0$24M$196M+ $767M short-term inv.$27M-$6.1M operating cash flowreport ↗
2023-Q3$0$18M$37M+ $339M short-term inv.$23M-$20M operating cash flowreport ↗
2023-Q2$0$14M$70M+ $323M short-term inv.$19M-$11M operating cash flowreport ↗
2023-Q1$0$11M$18M+ $117M short-term inv.$20M-$25M operating cash flowreport ↗
2022-Q3$0$12M$29M+ $126M short-term inv.$16M-$14M operating cash flowreport ↗
2022-Q2$0$14M$16M+ $153M short-term inv.$17M-$13M operating cash flowreport ↗
2022-Q1$0$13M$12M+ $172M short-term inv.$16M-$11M operating cash flowreport ↗
2021-Q3$0$11M$11M+ $205M short-term inv.$13M-$11M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$345M$166M+ $540M short-term inv.$90M-$279M operating cash flowreport ↗

For FY2025, Viking Therapeutics reported no revenue ($0M, flat YoY), R&D spend of $344.96M, up 239.4% YoY, and a net loss of $359.64M. Year-end cash and equivalents were $165.81M, and the company reported cash, cash equivalents and short-term investments of $706M.

Operationally, oral VK2735 is planned to advance into Phase 3 for obesity in 3Q26, while the Phase 3 VANQUISH trials for subcutaneous VK2735 remain ongoing, with VANQUISH-1 enrollment complete and VANQUISH-2 nearing full enrollment. A VK2735 maintenance dosing study is fully enrolled with data expected in 3Q26, and the company plans to file an IND for its novel amylin agonist this quarter. The company also highlighted VENTURE data presentations at ObesityWeek and a publication in the journal Obesity.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0$102M$27M+ $876M short-term inv.$27M-$88M operating cash flowreport ↗
2023-FY$0$64M$56M+ $307M short-term inv.$21M-$73M operating cash flowreport ↗
2022-FY$0$54M$37M+ $119M short-term inv.$17M-$48M operating cash flowreport ↗
2021-FY$0$45M$26M+ $176M short-term inv.$14M-$48M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($150K), 16 sales ($18.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-01Kelly-Gemmell Dorothy Elizabeth · directorAward / grant6,333——Form 4
2026-08-01Kelly-Gemmell Dorothy Elizabeth · directorAward / grant (derivative)40,800——Form 4
2026-07-29Mancini Marianna · Chief Operating OfficerOpen-market sale18,217$33.47$610KForm 4
2026-07-29ZANTE GREG · Chief Financial OfficerOpen-market sale21,217$33.47$710KForm 4
2026-07-29Lian Brian · director, President & CEOOpen-market sale148,517$33.32$4.9MForm 4
2026-07-28Mancini Marianna · Chief Operating OfficerAward / grant31,667——Form 4
2026-07-28ZANTE GREG · Chief Financial OfficerAward / grant31,667——Form 4
2026-07-28Lian Brian · director, President & CEOAward / grant221,667——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 407 reporting institutions held 73.2M shares ($2.4B, 57.4% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.6,880,290$223.9M
2FMR LLC6,024,753$196.0M
3VANGUARD CAPITAL MANAGEMENT LLC5,012,502$163.1M
4VANGUARD PORTFOLIO MANAGEMENT LLC4,464,298$145.3M
5TWO SIGMA INVESTMENTS, LP4,432,142$144.2M
6STATE STREET CORP4,395,557$143.0M
7RAYMOND JAMES FINANCIAL INC2,075,403$113.5M
8MORGAN STANLEY3,013,928$98.1M
9GEODE CAPITAL MANAGEMENT, LLC2,082,067$67.8M
10AMERICAN CENTURY COMPANIES INC2,078,577$67.6M
11AMERIPRISE FINANCIAL INC1,678,745$54.6M
12D. E. Shaw & Co., Inc.1,676,713$54.6M
13UBS Group AG1,347,472$43.8M
14CITADEL ADVISORS LLC1,262,221$41.1M
15GOLDMAN SACHS GROUP INC960,570$31.3M